1. The ONTARGET Investigators.  Telmisartan, ramipril, or both in patients at high risk for vascular events.  N Eng J Med.2008;358:1547-1559.
2. The TRANSCEND Investigators 2008. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. The Lancet 2008;372:1174-1183.
3. World Health Organization, Fact Sheet 317: Cardiovascular Diseases September 2009. http://www.who.int/mediacentre/factsheets/fs317/en/index.html. Accessed October 2009.
4. European Heart Network – CVD Statistics. http://www.ehnheart.org/content/sectionintro.asp?level0=1457 Accessed October 2009.
5. British Heart Foundation Statistics Website http://www.heartstats.org/datapage.asp?id=754 Accessed October 2009.
6. J Mackay, G Mensah, Atlas of Heart Disease and Stroke.  2004 World Health Organization. Geneva.